Alkontrol-herbal Effects on Alcohol Drinking (Alkontrol)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT03099590 |
Recruitment Status :
Completed
First Posted : April 4, 2017
Last Update Posted : July 29, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Alcohol Drinking Alcohol Use Disorder Alcohol Abstinence | Dietary Supplement: kudzu extract, puerarin Dietary Supplement: Placebo control | Phase 2 |
Over the past 15 years, the Behavioral Psychopharmacology Research Lab at McLean Hospital has extensively studied kudzu extract and demonstrated its safety and efficacy in healthy control subjects as well as in heavy binge drinkers. The relative success of our recent outpatient trial of kudzu extract demonstrated a modest decrease in drinking, reduction in the number of heavy drinking days, and significant increase in the number of days abstinent. This suggests that Alkontrol-herbal, kudzu extract, may be a useful adjunct in treating alcohol use disorders.
Participants will enroll in a 14-week study (2 weeks of baseline, 8 weeks of treatment, and 4 weeks of follow-up) investigating the impact that Alkontrol-herbal has on alcohol intake in a population (age 21-60 years) seeking treatment for an alcohol use disorder. Participants will take 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) t.i.d.; matched sugar beet placebo capsules will serve as placebo. Subjects will come to the lab three times a week to provide urine samples that can be tested for medication compliance through a biochemical marker, acetazolamide, included in the medication capsules. Participants will record their alcohol intake through daily diaries and a wrist actigraphy device, which will also monitor their sleep/wake activity.
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 28 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Intervention Model Description: | Half of the enrolled subjects will receive treatment with Alkontrol-herbal, kudzu extract, and half will receive a placebo control. |
Masking: | Double (Participant, Care Provider) |
Masking Description: | Neither the participants nor the study personnel providing the care/assessments will know whether the treatment received is active or placebo |
Primary Purpose: | Treatment |
Official Title: | Alkontrol-herbal (Isoflavone) Effects on Alcohol Drinking in an Outpatient Setting |
Actual Study Start Date : | January 1, 2018 |
Actual Primary Completion Date : | March 1, 2020 |
Actual Study Completion Date : | July 1, 2020 |

Arm | Intervention/treatment |
---|---|
Experimental: Active Treatment, Alkontrol-herbal
Alkontrol-herbal, a kudzu extract which contains 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
|
Dietary Supplement: kudzu extract, puerarin
Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
Other Name: Alkontrol-herbal |
Placebo Comparator: Placebo Control
Matched dextran containing capsules will serve as placebo.
|
Dietary Supplement: Placebo control
Matched sugar beet placebo capsules will serve as placebo. |
- percent days abstinent [ Time Frame: change from baseline to post 8 weeks of treatment ]percent days abstinent from alcohol
- drinks/day [ Time Frame: change from baseline to post 8 weeks of treatment ]number of alcoholic drinks/day reported
- number (or percent) of heavy drinking days [ Time Frame: change from baseline to post 8 weeks of treatment ]number (or percent) of heavy drinking days
- percent days abstinent [ Time Frame: change from baseline to 4 weeks follow-up post-treatment ]percent days abstinent from alcohol
- drinks/day [ Time Frame: change from baseline to 4 weeks follow-up post-treatment ]number of alcoholic drinks/day reported
- number (or percent) of heavy drinking days [ Time Frame: change from baseline to 4 weeks follow-up post-treatment ]number (or percent) of heavy drinking days

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 21 Years to 60 Years (Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject can understand and comply with the protocol
- Good physical and mental health (normal physical exam, ECG, blood and urine chemistries, including absence of history or laboratory evidence of diabetes)
- Body Mass Index between 18-30, inclusive
- Age 21-60 years (age will be verified by driver's license or other valid form of identification)
- Meet criteria for current Moderate or Severe (4+ symptoms) Alcohol Use Disorder per the DSM-5; If attending a self-help treatment group (e.g., AA) at time of the screening visit, subject must agree to continue attending these groups for the duration of the study
- Seeking treatment for an Alcohol Use Disorder
- Drink 20-35 (or more) drink per week
- Report drinking on 80% of days in the past 90 days
- Have a stable living situation with current postal address
Exclusion Criteria:
- Subject meets DSM-5 criteria for major depression and/or bipolar disorder, and is not medically, pharmacologically, or clinically stable. Subjects who currently meet criteria for minor depression or bipolar disorder and have been clinically stable (including medications) for the past 2 months may participate in the study, at the investigator's discretion
- Concurrent diagnosis of any other Axis I disorder, including any substance use disorder besides alcohol use disorder Maintained on an antipsychotic or anti-seizure medication; Current prescription for benzodiazepines
- Presence of neurological, infectious, or neoplastic disease or a chronic medical disorder
- Tobacco use greater than 10 cigarettes per day
- Currently abstaining from consuming alcoholic beverages longer than 10 days
- History of major head trauma resulting in cognitive impairment or history of seizure disorder
- Heavy caffeine use (greater than 500 mg on a regular, daily basis)
- Subject has active hepatitis and/or aspartate aminotransferase (AST), alanine aminotransferase (ALT) > 3x the upper limit of normal
- For female volunteers, a positive pregnancy test (female subjects must agree to an approved method of contraception for the duration of the study)

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03099590
United States, Massachusetts | |
McLean Hospital | |
Belmont, Massachusetts, United States, 02478 |
Responsible Party: | Scott Lukas, Director - McLean Imaging Center, Mclean Hospital |
ClinicalTrials.gov Identifier: | NCT03099590 |
Other Study ID Numbers: |
2017P000109 |
First Posted: | April 4, 2017 Key Record Dates |
Last Update Posted: | July 29, 2020 |
Last Verified: | July 2020 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Alcoholism Alcohol Drinking Alcohol Abstinence Drinking Behavior Alcohol-Related Disorders |
Substance-Related Disorders Chemically-Induced Disorders Mental Disorders Puerarin Vasodilator Agents |